**Emrock Corporation Limited (BSE: 531676)** is an Indian listed entity currently undergoing a high-velocity strategic transformation. Following a total change in management control in **January 2025**, the company has pivoted from a niche Mumbai-based real estate and **Transfer of Development Rights (TDR)** firm into a diversified multi-sector enterprise. The "New Emrock" now operates across **Renewable Energy**, **Pharmaceuticals**, **Hospitality**, and **Infrastructure**, backed by a significantly expanded capital base and a relocation of its corporate headquarters to **Ahmedabad, Gujarat**. --- ### **Strategic Pivot & Corporate Evolution** The company’s trajectory was redefined by a successful **Open Offer** and **Share Purchase Agreement (SPA)** finalized in early **2025**, which resulted in a complete overhaul of the Board of Directors and ownership structure. | Feature | Pre-Transition (Pre-2025) | Post-Transition (Current) | | :--- | :--- | :--- | | **Company Name** | Vaghani Techno-Build Limited (VTBL) | **Emrock Corporation Limited** | | **Promoter Group** | Govind J. Vaghani & Associates | **Jatinkumar T. Patel, Parth T. Patel, Arjunkumar J. Patel** | | **Promoter Holding** | **~64.33%** | **73.87%** | | **Registered Office** | Mumbai, Maharashtra | **Ahmedabad, Gujarat** | | **Core Focus** | TDR Trading & Construction | **Solar Energy, Pharma, Hospitality, Real Estate** | --- ### **Diversified Business Verticals** #### **1. Renewable Energy & Sustainability** This is a primary growth engine for the company, focusing on the generation and distribution of green power. * **Solar Power Agreement:** The company has secured a long-term contract with **Uttar Gujarat Vij Company Limited (UGVCL)** to supply **4 MW** of solar power. * **Contract Duration:** **25-year** Power Purchase Agreement (PPA). * **Target Commissioning:** **December 31, 2025**. * **Expanded Scope:** The company’s mandate now includes **Green Hydrogen**, **Wind Energy**, **Bio-fuels**, and **Waste-to-Energy** (converting biomass/solid waste into power or synthetic gas). #### **2. Pharmaceuticals & Healthcare Value Chain** Emrock has established a comprehensive framework to operate across the entire pharmaceutical lifecycle, from R&D to global distribution. * **Therapeutic Range:** Allopathic, Ayurvedic, Homeopathic, Herbal, and **Nutraceuticals**. * **Product Depth:** Antibiotics, enzymes, steroids, vitamins, hormones, and **immunological biologicals** (vaccines/toxins). * **Medical Infrastructure:** Manufacturing of surgical dressings, **diagnostic agents**, and medical devices. * **Veterinary Division:** Specialized medicaments for livestock and poultry. #### **3. Hospitality & Event Infrastructure** Through a **39%** stake in **Emrock Signature Hospitality LLP**, the company is developing a premium event hub in Ahmedabad. * **Project Components:** A **1,400-capacity** Banquet Hall, a **1,200-capacity** Party Plot, and a **250-seat** Restaurant. * **Investment Scale:** Estimated project cost of **₹12 Crores to ₹15 Crores**. * **Completion Target:** **December 31, 2026**. #### **4. Real Estate & TDR Trading** The legacy business remains an active asset class, though it is being integrated into a broader infrastructure play. * **TDR Operations:** Trading of **Transfer of Development Rights** and projects generating **Development Rights Certificates (DRC)**. * **Infrastructure Mandate:** New objects include the construction of roads, bridges, railways, gas lines, and ports. --- ### **Financial Performance & Capital Structure** The company has successfully transitioned from a loss-making entity to a profitable one during the management handover. #### **Key Financial Metrics (FY 2024-25)** * **Net Profit:** **₹17.00 Lakhs** (recovering from a **₹10.12 Lakhs** loss in FY 2023-24). * **Total Borrowings:** **₹86.44 Lakhs** (up from zero, reflecting new project mobilization). * **Cash & Equivalents:** **₹3.59 Lakhs**. #### **Capital Expansion & Fund Utilization** To fuel its multi-sector expansion, the company has aggressively scaled its financial capacity: * **Authorised Share Capital:** Increased from **₹10 Crores** to **₹30 Crores**. * **Borrowing Limits:** Set at a ceiling of **₹350 Crores**. * **Investment/Loan Limit (u/s 186):** **₹150 Crores**. * **Warrant Issuance:** In **May 2025**, the company allotted **2,35,35,491 convertible warrants** at **₹11** per warrant (Totaling **₹25.89 Crores**). * **Equity Conversion:** As of December 2025, the paid-up capital rose to **₹15.82 Crores** following the conversion of **50,00,000** warrants. **1,29,35,491** warrants remain pending for conversion. --- ### **Operational Risk Profile** Investors should note the following risks associated with the company’s transition and sector exposures: * **Regulatory & TDR Volatility:** The valuation of **TDR inventory** is highly sensitive to **Municipal authority** policies and the **Development Control & Promotion Regulation 2034**. Delays in DRC issuance can impact liquidity. * **Solar Irradiance & Policy Risk:** Revenue from the solar segment is dependent on weather patterns and potential retrospective changes in state-level **Open Access regulations** or tariffs. * **Governance Gaps:** The company has faced historical compliance challenges, including a period where the **Audit Committee** was not properly constituted (late 2023 to mid-2024) and delays in the **SPA** execution due to frozen promoter accounts. * **Contingent Liabilities:** There is a pending disputed **Income Tax** liability of **₹1,05,94,909**. * **Public Float Compliance:** With promoter holding at **73.87%**, the company must ensure it maintains the **25% Minimum Public Shareholding (MPS)** threshold as per SEBI norms. --- ### **Listing & Surveillance Status** * **Exchange:** **BSE Limited** (Scrip Code: **531676**). * **Surveillance:** Previously positioned under **Graded Surveillance Measure (GSM) Stage 4** (as of late 2024). * **Capitalization:** **5,22,00,000** equity shares (pre-conversion) with a face value of **₹10** each. * **Subsidiaries:** Currently has **no subsidiaries**; operates through direct ownership and LLPs.